已收盘 05-08 16:00:00 美东时间
-0.008
-2.54%
Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completionPOTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma, Inc. (NYSE:IGC)
04-20 20:33
今日重点评级关注:Ascendiant Capital:维持IGC Pharma"买入"评级,目标价从5美元升至5.25美元;Benchmark:维持Direct Digital Holdings"投机性买入"评级,目标价从2美元升至8美元
04-09 10:15
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5 to $5.25.
04-08 17:56
https://cannabiswire.com/newsletters/scoop-medicare-cbd-pilot-will-allow-some-thc-in-products/?free_read=1773920530418
03-19 22:30
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent increase over losses of $(0.02) per share from the same period
03-19 21:25
今日重点评级关注:Ascendiant Capital:维持IGC Pharma"买入"评级,目标价从4.75美元升至5美元;Brookline Capital:维持C4 Therapeutics"买入"评级,目标价从20美元升至30美元
02-24 10:27
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $4.75 to $5.
02-23 18:00
https://www.marijuanamoment.net/gop-congressman-isnt-sure-marijuana-rescheduling-is-a-doj-priority-but-remains-optimistic-about-progress-under-trump/
02-11 00:19
- Adds world renowned GNA site to broaden genetic diversity and strengthen path toward 2026 data catalyst -
02-09 21:38
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $191.000 thousand
2025-11-17 21:38